ArticleOpen heart2026
Feasibility and outcomes of an automated high-alert NT-proBNP pathway.
Article in Open heart, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
15 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundNT-proBNP is a key biomarker in heart failure (HF). Patients with markedly elevated levels are at high risk of adverse outcomes but experience delays in specialist care. Evidence on the impact of an automated, high-threshold NT-proBNP referral pathway embedded in electronic patient records is limited.
methodsAll NT-proBNP results >5000 pg/mL over a 12-month period triggered automatic HF team referral. Referrals were categorised as inpatients, outpatients with known HF, outpatients not suitable for follow-up or new outpatients without a diagnosis of HF who were eligible for enrolment. Eligible patients were offered echocardiography and review within 48 hours, with treatment and outcome data collected prospectively. A retrospective comparator cohort included all outpatient NT-proBNP results >5000 pg/mL from patients not known to the HF service in the 12 months before implementation.
resultsOver 12 months, 889 referrals were generated: 417 (47%) inpatients, 370 (42%) known outpatients, 59 (7%) not appropriate and 43 (5%) enrolled. Median time to review was 2 days, with 70% meeting the 48-hour target. Among enrolled patients (mean age 81, 56% male, median NT-proBNP 7480 pg/mL), HF with reduced ejection fraction (HFrEF) was diagnosed in 21 (49%), HF with mildly reduced ejection fraction in seven (16%), HF with preserved ejection fraction in 10 (23%) and severe aortic stenosis or new atrial fibrillation in four each (10%). At 12 weeks, 62% of patients had improved by at least one New York Heart Association class, and mean left ventricular ejection fraction increased from 27% to 45% in those with HFrEF. At 12 weeks, admission and mortality were 36% and 8%, respectively, compared with 35% and 12% in the retrospective cohort (n=60).
conclusionAn automated high-threshold NT-proBNP pathway is feasible and identifies very high-risk patients. Enrolled patients had rapid therapy optimisation, with observed improvements in symptoms and cardiac function.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.